Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia
A patient with chemotherapy-resistant acute monocytic leukemia who achieved complete remission (CR) after iron chelation therapy (ICT) with deferasirox is reported for the first time. A 73-year-old Japanese man with acute monocytic leukemia who was refractory to conventional remission induction chem...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2011-05, Vol.31 (5), p.1741-1744 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1744 |
|---|---|
| container_issue | 5 |
| container_start_page | 1741 |
| container_title | Anticancer research |
| container_volume | 31 |
| creator | FUKUSHIMA, Toshihiro KAWABATA, Hiroshi MASAKI, Yasufumi HIROSE, Yuko UMEHARA, Hisanori NAKAMURA, Takuji IWAO, Haruka NAKAJIMA, Akio MIKI, Miyuki SAKAI, Tomoyuki SAWAKI, Toshioki FUJITA, Yoshimasa TANAKA, Masao |
| description | A patient with chemotherapy-resistant acute monocytic leukemia who achieved complete remission (CR) after iron chelation therapy (ICT) with deferasirox is reported for the first time. A 73-year-old Japanese man with acute monocytic leukemia who was refractory to conventional remission induction chemotherapies achieved a partial response, with some improvement of his hemoglobin level and white blood cell count after gemtuzumab ozogamicin (GO) treatment. Seven months after GO treatment, the disease relapsed and the patient developed pancytopenia. He declined further chemotherapy, and started receiving 1,200-1,800 ml of packed red blood cell transfusion per month together with ICT with deferasirox (baseline serum ferritin level was 1,412 ng/ml). Twelve months after the initiation of deferasirox, the patient's serum ferritin level decreased to below 1,000 ng/ml and deferasirox was discontinued. Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR.
CR was achieved after ICT with deferasirox in a patient with acute myelogenous leukemia, suggesting that deferasirox may have an antileukemic effect in the clinical setting. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_907163014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>868998147</sourcerecordid><originalsourceid>FETCH-LOGICAL-p272t-c11d6e2a8904c48bf2ed2bf5c21e23911b60bcd03cb5083a2384220e3c3ef6a03</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMouq7-BclFPBXy0TbpcalfCyuKrOeSplM22jY1SdG9-8ON7IpHTzPDPO8DMwdoRkVBE5FxcohmhGUkEYRkJ-jU-1dC8ryQ_BidMJpTwTifoa-lswMuN9CpYGK33oBT4xZ_mLDB19DGyRtnP_FyaCYNDS5tP3YQAD9Db7z_yZgBK_wU8zCEXTD6eht2qsSBNz6ouFvoKQYf7GD1NhiNVzC9RYs6Q0et6jyc7-scvdzerMv7ZPV4tywXq2RkgoVEU9rkwJQsSKpTWbcMGla3mWYUGC8orXNS64ZwXWdEcsW4TBkjwDWHNleEz9HVzjs6-z6BD1U8QUPXqQHs5KuCCJpzQtN_SZnLopA0FZG82JNT3UNTjc70ym2r3xdH4HIPKK9V1zo1aOP_uJTGe0TKvwFMNYdv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>868998147</pqid></control><display><type>article</type><title>Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>FUKUSHIMA, Toshihiro ; KAWABATA, Hiroshi ; MASAKI, Yasufumi ; HIROSE, Yuko ; UMEHARA, Hisanori ; NAKAMURA, Takuji ; IWAO, Haruka ; NAKAJIMA, Akio ; MIKI, Miyuki ; SAKAI, Tomoyuki ; SAWAKI, Toshioki ; FUJITA, Yoshimasa ; TANAKA, Masao</creator><creatorcontrib>FUKUSHIMA, Toshihiro ; KAWABATA, Hiroshi ; MASAKI, Yasufumi ; HIROSE, Yuko ; UMEHARA, Hisanori ; NAKAMURA, Takuji ; IWAO, Haruka ; NAKAJIMA, Akio ; MIKI, Miyuki ; SAKAI, Tomoyuki ; SAWAKI, Toshioki ; FUJITA, Yoshimasa ; TANAKA, Masao</creatorcontrib><description>A patient with chemotherapy-resistant acute monocytic leukemia who achieved complete remission (CR) after iron chelation therapy (ICT) with deferasirox is reported for the first time. A 73-year-old Japanese man with acute monocytic leukemia who was refractory to conventional remission induction chemotherapies achieved a partial response, with some improvement of his hemoglobin level and white blood cell count after gemtuzumab ozogamicin (GO) treatment. Seven months after GO treatment, the disease relapsed and the patient developed pancytopenia. He declined further chemotherapy, and started receiving 1,200-1,800 ml of packed red blood cell transfusion per month together with ICT with deferasirox (baseline serum ferritin level was 1,412 ng/ml). Twelve months after the initiation of deferasirox, the patient's serum ferritin level decreased to below 1,000 ng/ml and deferasirox was discontinued. Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR.
CR was achieved after ICT with deferasirox in a patient with acute myelogenous leukemia, suggesting that deferasirox may have an antileukemic effect in the clinical setting.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 21617233</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Aminoglycosides - adverse effects ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - adverse effects ; Benzoates - therapeutic use ; Biological and medical sciences ; Chelation Therapy ; Drug Resistance, Neoplasm - drug effects ; Erythrocyte Transfusion ; Hematologic and hematopoietic diseases ; Humans ; Iron Chelating Agents - therapeutic use ; Leukemia, Myelomonocytic, Acute - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Remission Induction ; Salvage Therapy ; Treatment Outcome ; Triazoles - therapeutic use ; Tumors</subject><ispartof>Anticancer research, 2011-05, Vol.31 (5), p.1741-1744</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24189074$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21617233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUKUSHIMA, Toshihiro</creatorcontrib><creatorcontrib>KAWABATA, Hiroshi</creatorcontrib><creatorcontrib>MASAKI, Yasufumi</creatorcontrib><creatorcontrib>HIROSE, Yuko</creatorcontrib><creatorcontrib>UMEHARA, Hisanori</creatorcontrib><creatorcontrib>NAKAMURA, Takuji</creatorcontrib><creatorcontrib>IWAO, Haruka</creatorcontrib><creatorcontrib>NAKAJIMA, Akio</creatorcontrib><creatorcontrib>MIKI, Miyuki</creatorcontrib><creatorcontrib>SAKAI, Tomoyuki</creatorcontrib><creatorcontrib>SAWAKI, Toshioki</creatorcontrib><creatorcontrib>FUJITA, Yoshimasa</creatorcontrib><creatorcontrib>TANAKA, Masao</creatorcontrib><title>Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>A patient with chemotherapy-resistant acute monocytic leukemia who achieved complete remission (CR) after iron chelation therapy (ICT) with deferasirox is reported for the first time. A 73-year-old Japanese man with acute monocytic leukemia who was refractory to conventional remission induction chemotherapies achieved a partial response, with some improvement of his hemoglobin level and white blood cell count after gemtuzumab ozogamicin (GO) treatment. Seven months after GO treatment, the disease relapsed and the patient developed pancytopenia. He declined further chemotherapy, and started receiving 1,200-1,800 ml of packed red blood cell transfusion per month together with ICT with deferasirox (baseline serum ferritin level was 1,412 ng/ml). Twelve months after the initiation of deferasirox, the patient's serum ferritin level decreased to below 1,000 ng/ml and deferasirox was discontinued. Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR.
CR was achieved after ICT with deferasirox in a patient with acute myelogenous leukemia, suggesting that deferasirox may have an antileukemic effect in the clinical setting.</description><subject>Aged</subject><subject>Aminoglycosides - adverse effects</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Benzoates - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chelation Therapy</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Erythrocyte Transfusion</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Iron Chelating Agents - therapeutic use</subject><subject>Leukemia, Myelomonocytic, Acute - drug therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Remission Induction</subject><subject>Salvage Therapy</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMouq7-BclFPBXy0TbpcalfCyuKrOeSplM22jY1SdG9-8ON7IpHTzPDPO8DMwdoRkVBE5FxcohmhGUkEYRkJ-jU-1dC8ryQ_BidMJpTwTifoa-lswMuN9CpYGK33oBT4xZ_mLDB19DGyRtnP_FyaCYNDS5tP3YQAD9Db7z_yZgBK_wU8zCEXTD6eht2qsSBNz6ouFvoKQYf7GD1NhiNVzC9RYs6Q0et6jyc7-scvdzerMv7ZPV4tywXq2RkgoVEU9rkwJQsSKpTWbcMGla3mWYUGC8orXNS64ZwXWdEcsW4TBkjwDWHNleEz9HVzjs6-z6BD1U8QUPXqQHs5KuCCJpzQtN_SZnLopA0FZG82JNT3UNTjc70ym2r3xdH4HIPKK9V1zo1aOP_uJTGe0TKvwFMNYdv</recordid><startdate>20110501</startdate><enddate>20110501</enddate><creator>FUKUSHIMA, Toshihiro</creator><creator>KAWABATA, Hiroshi</creator><creator>MASAKI, Yasufumi</creator><creator>HIROSE, Yuko</creator><creator>UMEHARA, Hisanori</creator><creator>NAKAMURA, Takuji</creator><creator>IWAO, Haruka</creator><creator>NAKAJIMA, Akio</creator><creator>MIKI, Miyuki</creator><creator>SAKAI, Tomoyuki</creator><creator>SAWAKI, Toshioki</creator><creator>FUJITA, Yoshimasa</creator><creator>TANAKA, Masao</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20110501</creationdate><title>Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia</title><author>FUKUSHIMA, Toshihiro ; KAWABATA, Hiroshi ; MASAKI, Yasufumi ; HIROSE, Yuko ; UMEHARA, Hisanori ; NAKAMURA, Takuji ; IWAO, Haruka ; NAKAJIMA, Akio ; MIKI, Miyuki ; SAKAI, Tomoyuki ; SAWAKI, Toshioki ; FUJITA, Yoshimasa ; TANAKA, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p272t-c11d6e2a8904c48bf2ed2bf5c21e23911b60bcd03cb5083a2384220e3c3ef6a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aminoglycosides - adverse effects</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Benzoates - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chelation Therapy</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Erythrocyte Transfusion</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Iron Chelating Agents - therapeutic use</topic><topic>Leukemia, Myelomonocytic, Acute - drug therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Remission Induction</topic><topic>Salvage Therapy</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUKUSHIMA, Toshihiro</creatorcontrib><creatorcontrib>KAWABATA, Hiroshi</creatorcontrib><creatorcontrib>MASAKI, Yasufumi</creatorcontrib><creatorcontrib>HIROSE, Yuko</creatorcontrib><creatorcontrib>UMEHARA, Hisanori</creatorcontrib><creatorcontrib>NAKAMURA, Takuji</creatorcontrib><creatorcontrib>IWAO, Haruka</creatorcontrib><creatorcontrib>NAKAJIMA, Akio</creatorcontrib><creatorcontrib>MIKI, Miyuki</creatorcontrib><creatorcontrib>SAKAI, Tomoyuki</creatorcontrib><creatorcontrib>SAWAKI, Toshioki</creatorcontrib><creatorcontrib>FUJITA, Yoshimasa</creatorcontrib><creatorcontrib>TANAKA, Masao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUKUSHIMA, Toshihiro</au><au>KAWABATA, Hiroshi</au><au>MASAKI, Yasufumi</au><au>HIROSE, Yuko</au><au>UMEHARA, Hisanori</au><au>NAKAMURA, Takuji</au><au>IWAO, Haruka</au><au>NAKAJIMA, Akio</au><au>MIKI, Miyuki</au><au>SAKAI, Tomoyuki</au><au>SAWAKI, Toshioki</au><au>FUJITA, Yoshimasa</au><au>TANAKA, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2011-05-01</date><risdate>2011</risdate><volume>31</volume><issue>5</issue><spage>1741</spage><epage>1744</epage><pages>1741-1744</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>A patient with chemotherapy-resistant acute monocytic leukemia who achieved complete remission (CR) after iron chelation therapy (ICT) with deferasirox is reported for the first time. A 73-year-old Japanese man with acute monocytic leukemia who was refractory to conventional remission induction chemotherapies achieved a partial response, with some improvement of his hemoglobin level and white blood cell count after gemtuzumab ozogamicin (GO) treatment. Seven months after GO treatment, the disease relapsed and the patient developed pancytopenia. He declined further chemotherapy, and started receiving 1,200-1,800 ml of packed red blood cell transfusion per month together with ICT with deferasirox (baseline serum ferritin level was 1,412 ng/ml). Twelve months after the initiation of deferasirox, the patient's serum ferritin level decreased to below 1,000 ng/ml and deferasirox was discontinued. Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR.
CR was achieved after ICT with deferasirox in a patient with acute myelogenous leukemia, suggesting that deferasirox may have an antileukemic effect in the clinical setting.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>21617233</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2011-05, Vol.31 (5), p.1741-1744 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907163014 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aminoglycosides - adverse effects Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - adverse effects Benzoates - therapeutic use Biological and medical sciences Chelation Therapy Drug Resistance, Neoplasm - drug effects Erythrocyte Transfusion Hematologic and hematopoietic diseases Humans Iron Chelating Agents - therapeutic use Leukemia, Myelomonocytic, Acute - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Remission Induction Salvage Therapy Treatment Outcome Triazoles - therapeutic use Tumors |
| title | Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A41%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Iron%20Chelation%20Therapy%20with%20Deferasirox%20Induced%20Complete%20Remission%20in%20a%20Patient%20with%20Chemotherapy-resistant%20Acute%20Monocytic%20Leukemia&rft.jtitle=Anticancer%20research&rft.au=FUKUSHIMA,%20Toshihiro&rft.date=2011-05-01&rft.volume=31&rft.issue=5&rft.spage=1741&rft.epage=1744&rft.pages=1741-1744&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E868998147%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=868998147&rft_id=info:pmid/21617233&rfr_iscdi=true |